Table 5. Therapeutic classes characteristics for chronic regimens.
| Medications in each regimen | Intervention | Control | ||
|---|---|---|---|---|
| Base line | Study exit | Base line | Study exit | |
| n=516 | n=506 | n=541 | n=556 | |
| Antihyperglycaemic medication | 253 (49) | 249 (49.2) | 274 (50.6) | 280 (50.4) |
| Insulin | 16 (6.3) | 17 (6.8) | 11 (4) | 13 (4.6) |
| GLP | 34 (13.4) | 39 (15.7) | 42 (15.3) | 44 (15.7) |
| Metformin | 84 (33.2) | 84 (33.7) | 86 (31.4) | 83 (29.6) |
| Sulfonylurea | 32 (12.6) | 28 (11.2) | 36 (13.1) | 34 (12.1) |
| TZD | 11 (4.3) | 10 (4) | 6 (2.2) | 5 (1.9) |
| SGLT2 | 49 (19.4) | 52 (20.9) | 60 (21.9) | 64 (22.9) |
| DPP4 inhibitor | 27 (10.7) | 19 (7.6) | 33 (12) | 37 (13.2) |
| Antihypertensive drugs ¥ | 142 (27.5) | 138 (27.3) | 152 (28.1) | 163 (29.3) |
| Renin-angiotensin | 60 (42.2) | 63 (45.9) | 65 (42.8) | 69 (42.3) |
| Beta-blockers | 26 (18.3) | 24 (17.5) | 18 (11.8) | 19 (11.7) |
| Ca-channel BL | 36 (25.3) | 35 (25.5) | 42 (27.6) | 47 (28.8) |
| Diuretics | 17 (11.9) | 15 (10.9) | 22 (14.5) | 21 (12.9) |
| Other | 3 (2.1) | 1 (0.7) | 5 (3.3) | 7 (11.1) |
| Antihyperlipidaemic drugs # | 121 (23.4) | 119 (23.5) | 115 (21.3) | 113 (20.3) |
| Statins | 82 (67.8) | 81 (68.1) | 76 (66.1) | 74 (65.5) |
| Ezetimibe | 16 (13.2) | 15 (12.6) | 28 (24.3) | 26 (23) |
| Omega-3 | 12 (9.9) | 10 (8.4) | 4 (3.5) | 4 (3.5) |
| Pcsk9 inhibitors | 11 (9.1) | 13 (10.9) | 7 (6.1) | 9 (7.9) |
Data are n (%);
¥
MPIP (n=86), control (n=94);
#
MPIP (n=91), control (n=95); GLP-1, glucagon-like peptide 1agonists; DPP-4, dipeptidyl peptidase 4; Pcsk9, proprotein convertase subtilisin/kexin type 9; SGLT2, sodium-glucose co-transporter-2 inhibitor; TZD, thiazolidinedione.